Monopar Therapeutics announced it is planning to report over the next two months the interim go/no-go analysis for its Validive Phase 2b/3 VOICE trial, clinical data from its camsirubicin Phase 1b trial, and a preclinical progress update on its MNPR-101 RIT program. February 2023: Camsirubicin Phase 1b Clinical Trial Data Update: In addition to the previously reported improvement in median progression free survival over the prior camsirubicin Phase 2 study, Monopar plans to provide details of the Phase 1b trial’s improved toxicity and safety observed to date compared to doxorubicin. MNPR-101 Radioimmunotherapeutic Preclinical Data Update: Monopar plans to report an update on recently generated preclinical data and anticipated next steps with partner NorthStar Medical Radioisotopes. March 2023: Interim Go/no-go Analysis for Validive Phase 2b/3 VOICE Trial: Monopar expects to have the interim analysis completed and to report out the go/no-go decision during March 2023; in the intervening time, patient enrollment and addition of new sites continue in preparation for a potentially positive interim.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on MNPR:
- Monopar Announces Projected Timeline of Upcoming Q1 2023 Data Events for Validive, Camsirubicin, and MNPR-101 RIT
- Monopar Therapeutics initiated with a Buy at EF Hutton
- Monopar Therapeutics furthers camsirubicin trial past 4th cohort for ASTS
- Monopar Announces Successful Advancement of Camsirubicin Phase 1b Clinical Trial Past Fourth Cohort, Escalates Next to 650mg/m2
- Monopar Therapeutics announces MNPR-202 data from ongoing collaboration